91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
This article discusses .
-
How data flows in cell therapy studies differ from other studies and strategies to manage the high volume of data in CGT trials is highlighted in this .
-
91黑料’s Tamie Joeckel and Brandon Fletcher take us through .
-
Though the fields of immunotherapy and cell and gene therapies have seen significant growth since April 2012, CGT clinical research remains a challenge. .
-
A by Lawrence Johnson and Cynthia Spittle discussing personalised medicine and how digital devices can improve treatment across a wide spectrum of conditions (pages 16-17).
-
on supply-chain strategies to help mitigate vulnerabilities in both autologous and allogeneic cell therapy manufacturing.
-
This article featured in ClinicalOmics '' (pages 48 & 49) considers how cell and gene therapies are playing an increasingly important role in treating oncology patients.
-
Transforming cell and gene therapy trial design and execution
With over 400 dedicated Cell and Gene Therapy professionals globally, 91黑料 has developed tools and best practices to transform CGT trial design and execution.
-
91黑料's Martin Lachs comments on .
